Savient Pharmaceuticals, Inc.
http://www.savientpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Savient Pharmaceuticals, Inc.
Japan Looks For Role As Korean Ventures’ New Step To Global Market
Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.
US FDA's Delay In Acting On Moderna RSV Vaccine Adds To Growing List of User Fee Goal Misses
Administrative constraints adds Moderna’s mRNA-1345 to the recently increasing number of US FDA user fee goal date misses.
Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash
Ajax Therapeutics plans to take its type II JAK2 inhibitor into the clinic during the second half of 2024 with the aim of modifying disease in a way that first-generation type I inhibitors do not.
Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst
While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.
Company Information
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice